The impact of omidubicel on immune reconstitution and infections in cord blood transplant patients

References

• Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. Registry N Engl J Med. 2014;371(4):339–348.
   PubMed Web of Science ®Google Scholar
• Logan B, Maiers M, Sparapani R, et al. Optimal donor selection for hematopoietic cell transplantation using bayesian machine learning. JCO Clin Cancer Inform. 2021;5(5):494–507. doi: 10.1200/CCI.20.00185
   PubMedGoogle Scholar
• 2022 report to the community [internet]. Minneapolis (MN): Be The Match; 2023 Jun [cited 2023 Dec 17]. Available from: https://bethematch.org/workarea/downloadasset.aspx?id=15032390502
   Google Scholar
• Rocha V, Wagner J, Sobocinski K, et al. Graft-Versus-Host disease in Children Who Have Received a cord-blood or bone marrow transplant from an HLA-Identical sibling. N Engl J Med. 2000;342(25):1846–1854.
   PubMed Web of Science ®Google Scholar
• Montoro J, Piñana J, Moscardó F, et al. Infectious complications after umbilical cord-blood transplantation from unrelated donors. Mediterr J Hematol Infect Dis. 2016;8(1):e2016051.
   PubMedGoogle Scholar
• World Marrow Donor Association (WMDA) [Internet]. Leiden the Netherlands: WMDA [cited 2023 Dec 17]. Available from: https://wmda.info/cord-blood-other-cell-therapies/
   Google Scholar
• Brunstein C, Gutman J, Weisdorf D, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood. 2010;116(22):46693–46699.
   Web of Science ®Google Scholar
• Barker J, Weisdorf D, DeFor T, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 2005;105(3):1343–1347. doi: 10.1182/blood-2004-07-2717
   PubMed Web of Science ®Google Scholar
• Michel G, Galambrun C, Sirvent A, et al. Single- vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome. Blood. 2016;127(26):3450–3457. doi: 10.1182/blood-2016-01-694349
   PubMed Web of Science ®Google Scholar
• Van Besien K, Liu H, Jain N, et al. Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications. Biol Blood Marrow Transplant. 2013;19(5):682–691. doi: 10.1016/j.bbmt.2012.11.001
   PubMed Web of Science ®Google Scholar
• Peled T, Shoham H, Aschengrau D, et al. Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment. Exp Hematol. 2012;40(4):342–355.
   PubMed Web of Science ®Google Scholar
• Mehta R, Rezvani K, Shpall E. Cord blood expansion: a clinical advance. J Clin Oncol. 2019;37(5):363–366. doi: 10.1200/JCO.18.01789
   PubMed Web of Science ®Google Scholar
• Horwitz M, Stiff P, Cutler C, et al. Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. Blood. 2021;138(16):1429–1440. doi: 10.1182/blood.2021011719.
   PubMed Web of Science ®Google Scholar
• Horwitz M, Chao N, Rizzieri D, et al. Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. J Clin Invest. 2014;124(7):3121–3128. doi: 10.1172/JCI74556
   PubMed Web of Science ®Google Scholar
• SzabolcsP, Mazor R, Yackoubov D, et al. Immune reconstitution profiling suggests antiviral protection after transplantation with Omidubicel: a phase 3 substudy. Transplant Cell Ther. 2023;29(8):e5171–e12. doi: 10.1016/j.jtct.2023.04.018.
   Google Scholar
• FDA approves omidubicel to reduce time to neutrophil recovery and infection in patients with hematologic malignancies [internet]. (WA) (DC): FDA; 2023 Apr 17 [cited 2023 Dec 17]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-omidubicel-reduce-time-neutrophil-recovery-and-infection-patients-hematologic
   Google Scholar
• Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143–1238. doi: 10.1016/j.bbmt.2009.06.019
   PubMed Web of Science ®Google Scholar
• Parody R, Martino R, Rovira M, et al. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant. 2006;12(7):734–748. doi: 10.1016/j.bbmt.2006.03.007
   PubMed Web of Science ®Google Scholar
• Mehta R, Rezvani K. Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection. Virulence. 2016;7(8):901–916. doi: 10.1080/21505594.2016.1208866
   PubMed Web of Science ®Google Scholar
• Elfeky R, Lazareva A, Qasim W, et al. Immune reconstitution following hematopoietic stem cell transplantation using different stem cell sources. Expert Rev Clin Immunol. 2019;15(7):735–751. doi: 10.1080/1744666X.2019.1612746
   PubMed Web of Science ®Google Scholar
• Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood. 2010;115(19):3861–3868. doi: 10.1182/blood-2009-12-234096
   PubMed Web of Science ®Google Scholar
• Dulphy N, Haas P, Busson M, et al. An unusual CD56brightCD16low NK cell subset dominates the early posttransplant period following HLA-Matched hematopoietic stem cell transplantation. J Immunol. 2008;181(3):2227–2237. doi: 10.4049/jimmunol.181.3.2227
   PubMed Web of Science ®Google Scholar
• van den Brink M, Velardi E, Perales M. Immune reconstitution following stem cell transplantation. Hematology Am Soc Hematol Educ Program. 2015;2015(1):215–219. doi: 10.1182/asheducation-2015.1.215
   PubMedGoogle Scholar
• Mackall C, Fry T, Gress R, et al. Background to hematopoietic cell transplantation, including post transplant immune recovery. Bone Marrow Transplant. 2009;44(8):457–462. doi: 10.1038/bmt.2009.255
   PubMed Web of Science ®Google Scholar
• Yanir A, Schulz A, Lawitschka A, et al. Immune reconstitution after allogeneic haematopoietic cell transplantation: from observational studies to targeted interventions. Front Pediatr. 2022;9(786017). doi: 10.3389/fped.2021.786017
   PubMedGoogle Scholar
• Velardi E, Tsai J, van den Brink M. T cell regeneration after immunological injury. Nat Rev Immunol. 2021;21(5):277–291. doi: 10.1038/s41577-020-00457-z
   PubMed Web of Science ®Google Scholar
• Talvensaari K, Clave E, Douay C, et al. A broad T-cell repertoire diversity and an efficient thymic function indicate a favorable long-term immune reconstitution after cord blood stem cell transplantation. Blood. 2002;99(4):1458–1464. doi: 10.1182/blood.V99.4.1458
   PubMed Web of Science ®Google Scholar
• Fedele R, Martino M, Garreffa C, et al. The impact of early CD4+ lymphocyte recovery on the outcome of patients who undergo allogeneic bone marrow or peripheral blood stem cell transplantation. Blood Transfus. 2012;10(2):174–180. doi: 10.2450/2012.0034-11
   PubMed Web of Science ®Google Scholar
• Berger M, Figari O, Bruno B, et al. Lymphocyte subsets recovery following allogeneic bone marrow transplantation (BMT): CD4+ cell count and transplant-related mortality. Bone Marrow Transplant. 2008;41(1):55–62. doi: 10.1038/sj.bmt.1705870
   PubMed Web of Science ®Google Scholar
• Politikos I, Lavery J, Hilden P, et al. Robust CD4+ T-cell recovery in adults transplanted with cord blood and no antithymocyte globulin. Blood Adv. 2020;4(1):191–202. doi: 10.1182/bloodadvances.2019000836
   PubMed Web of Science ®Google Scholar
• Bejanyan N, Brunstein C, Cao Q, et al. Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Blood Adv. 2018;2(8):909–922. doi: 10.1182/bloodadvances.2017014464
   PubMed Web of Science ®Google Scholar
• Klein A, Patel D, Gooding M, et al. T-Cell recovery in adults and children following umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2001;7(8):454–466. doi: 10.1016/s1083-8791(01)80013-6
   PubMed Web of Science ®Google Scholar
• Anasetti C, Logan B, Lee S, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367:1487–1496. doi: 10.1056/NEJMoa1203517
   PubMed Web of Science ®Google Scholar
• Pereira M, Pouch S, Scully B. Infections in Allogeneic Stem Cell Transplantation. Principles And Practice Of Transplant Infectious Diseases. 2018;209–226. doi: 10.1007/978-1-4939-9034-4_11
   Google Scholar
• Ge J, Yang T, Zhang L, et al. The incidence, risk factors and outcomes of early bloodstream infection in patients with malignant hematologic disease after unrelated cord blood transplantation: a retrospective study. BMC Infect Dis. 2018;18(654). doi: 10.1186/s12879-018-3575-x
   Google Scholar
• Leen A, Heslop H, Brenner M. Antiviral T-cell therapy. Immunol Rev. 2014;258(1):12–29. doi: 10.1111/imr.12138
   PubMed Web of Science ®Google Scholar
• Elmariah H, Brunstein C, Bejanyan N. Immune reconstitution after haploidentical donor and umbilical cord blood allogeneic hematopoietic cell transplantation. Life. 2021;11(2):102. doi: 10.3390/life11020102
   PubMedGoogle Scholar
• Anand S, Thomas S, Hyslop T, et al. Transplantation of ex vivo expanded umbilical cord blood (NiCord) decreases early infection and hospitalization. Biol Blood Marrow Transplant Biol Blood Marrow Transplant. 2017;23(7):1151–1157. doi: 10.1016/j.bbmt.2017.04.001
   PubMed Web of Science ®Google Scholar
• de Koning C, Tao W, Lacna A, et al. Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation. Bone Marrow Transplant. 2021;56:2826–2833. doi: 10.1038/s41409-021-01417-4
   PubMed Web of Science ®Google Scholar
• Lin C, Schwarzbach A, Sanz J, et al. Multicenter long-term follow-up of allogeneic hematopoietic cell transplantation with Omidubicel: a pooled analysis of five prospective clinical trials. Transplant Cell Ther. 2023;29(5):e3381–e3386.
   Google Scholar
• Nagler A, Mohty M. In 2022, which is preferred: haploidentical or cord transplant? Hematol Am Soc Hematol Educ Program. 2022;2022(1):64–73. doi: 10.1182/hematology.2022000327
   PubMedGoogle Scholar
• Mehta R, Saliba R, Rondon G, et al. Post-Transplantation Cyclophosphamide versus Tacrolimus and methotrexate graft-Versus-host disease prophylaxis for HLA-Matched donor Transplantation. Transplant Cell Ther. 2022;28(10):e6951–e10.
   Google Scholar
• Luznik L, O’Donnell P, Symons H, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–650. doi: 10.1016/j.bbmt.2008.03.005
   PubMed Web of Science ®Google Scholar
• Al Malki M, Devine S, Shaw B, et al. Access: a multi-center, phase II trial of HLA-Mismatched unrelated donor hematopoietic cell transplantation with post-transplantation cyclophosphamide for patients with hematologic malignancies. Blood. 2022;149(Supplement 1):7591–7593.
   Google Scholar
• Atilla E, Atilla P, Bozdag S, et al. A review of infectious complications after haploidentical hematopoietic stem cell transplantations. Infection. 2017;45(4):403–411. doi: 10.1007/s15010-017-1016-1
   PubMed Web of Science ®Google Scholar
• Massoud R, Gagelmann N, Fritzsche-Friedland U, et al. Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation. Haematologica. 2022;107(4):857–867. doi: 10.3324/haematol.2020.271445
   PubMed Web of Science ®Google Scholar
• Mikulska M, Bartalucci C, Raiola A, et al. Does PTCY increase the risk of infections? Blood Rev. 2023;2023(101092):101092. doi: 10.1016/j.blre.2023.101092
   Google Scholar
• Slade M, Goldsmith S, Romee R, et al. Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation. Transpl Infect Dis. 2017;19(1):e12629. doi: 10.1111/tid.12629
   PubMed Web of Science ®Google Scholar
• Crocchiolo R, Bramanti S, Vai A, et al. Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis. Transpl Infect Dis. 2015;17(2):242–249. doi: 10.1111/tid.12365
   PubMed Web of Science ®Google Scholar
• Fuchs E, O’Donnell P, Eapen M, et al. Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. Blood. 2021;137(3):420–428. doi: 10.1182/blood.2020007535
   PubMed Web of Science ®Google Scholar
• Ballen K, Woo AK, Chen M, et al. Infection rates among acute leukemia patients receiving alternative donor hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(9):1636–1645. doi: 10.1016/j.bbmt.2016.06.012
   PubMed Web of Science ®Google Scholar
• Bolanos-Meade J, Hamadani M, Wu J, et al. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host disease Prophylaxis. N Engl J Med. 2023388: 2338–2348. doi: 10.1056/NEJMoa2215943
   Google Scholar
• Sivaraman S, Sajeev G, Song Y, et al. Clinical outcomes following allogeneic hematopoietic cell transplantation with omidubicel or other donor sources in patients with hematologic malignancies: comparison of clinical trial results to center for international blood and marrow transplant research database controls. Blood. 2022;140:660–661. doi: 10.1182/blood-2022-162439
   Google Scholar
• Horwitz M, Schiller G, Tsai S, et al. Results of an open label expanded access study of omidubicel-onlv for allogeneic transplantation (allo-HCT) in patients with hematologic malignancies. Poster session presented at: Cord Blood Connect Meeting; 2023 Sep 8-10; Miami Beach, FL.
   Google Scholar
• Barker J, Kempenich J, Kurtzberg J, et al. CD34+ cell content of 126 341 cord blood units in the US inventory: implications for transplantation and banking. Blood Adv. 2019;3(8):1267–1271. doi: 10.1182/bloodadvances.2018029157
   PubMed Web of Science ®Google Scholar
• Remberger M, Torlen J, Ringden P, et al. Effect of total nucleated and CD34+ cell dose on outcome after allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther. 2015;21(5):889–893.
   Google Scholar
• Gauntner G, Brunstein C, Cao Q, et al. Association of CD34 cell dose with 5-year overall survival after peripheral blood allogeneic hematopoietic cell transplantation in adults with hematologic malignancies. Transplant Cell Ther. 2021;28(2):88–95.
   PubMedGoogle Scholar
• Horwitz M, Wease S, Blackwell B, et al. Phase I/II study of stem-cell transplantation using a single cord blood unit expanded ex vivo with nicotinamide. J Clin Oncol. 2019;37(5):367–374. doi: 10.1200/JCO.18.00053
   PubMed Web of Science ®Google Scholar
• Samour M, Aue G, Clara J, et al. Rapid engraftment, immune recovery, and resolution of transfusion dependence in treatment-refractory severe aplastic anemia following transplantation with ex vivo expanded umbilical cord ASH annual meeting (omidubicel). Blood. 2020 Dec 5-8;136(Supplement 1):37–38. doi: 10.1182/blood-2020-137771
   Google Scholar
• Parikh S, Brochstein J, Galamidi E, et al. Allogeneic stem cell transplantation with omidubicel in sickle cell disease. Blood Adv. 2021;9(5):843–852.
   Google Scholar
• Maziarz R, Gergis U, Edwards M, et al. Healthcare costs among patients with hematologic malignancies receiving allogeneic transplants: a US payer perspective. Blood Adv. 2023 [cited 17 Dec 2023]. Online ahead of print. doi: 10.1182/bloodadvances.2023011033
   Google Scholar
• Majhail N, Miller B, Dean R, et al. Hospitalization and healthcare resource utilization of omidubicel-only versus umbilical cord blood transplantation for hematologic malignancies: secondary analysis from a pivotal phase 3 clinical trial. Transplant Cell Ther. 2023;29(12):e7491–e7495. doi: 10.1016/j.jtct.2023.09.004
   Google Scholar
• Lin C, Sajeev G, Stiff P, et al. Health-related quality of life following allogeneic hematopoietic cell transplantation with omidubicel versus umbilical cord blood. Transplant Cell Ther. 2023;29(1):e521–e529. doi: 10.1016/j.jtct.2022.09.018
   Google Scholar